-
Mashup Score: 0Pinterest - 1 day(s) ago
More than 650 clinicians, advanced practice providers, nurses, administrators, trainees and other healthcare professionals participated Content is property of Cleveland Clinic and for news media use only. Panelists at Cleveland Clinic’s inaugural AI Summit for Healthcare Professionals. Healthcare leaders from around the country gathered at Cleveland Clinic’s inaugural AI Summit for Healthcare Professionals, diving into a dynamic array of topics shaping the future of medicine. The event was held on July
Source: newsroom.clevelandclinic.orgCategories: General Medicine NewsTweet
-
Mashup Score: 1
Jame Abraham: Our Inaugural Artificial Intelligence Conference / Albert Marinez, Artificial Intelligence Conference, Ben Shahshahani, Bethany Frampton,
Source: oncodaily.comCategories: General Medicine NewsTweet
-
Mashup Score: 43Human Epidermal Growth Factor Receptor 2 Positivity a Moving Target in the Era of Antibody-Drug Conjugates | JCO Oncology Practice - 3 day(s) ago
In 1986, approximately three decades after the discovery of estrogen and progesterone receptors, the human epidermal growth factor receptor 2 (HER2) oncogene was linked to aggressive breast cancers, which together defined the molecular subtypes of the disease. 1 Pioneering translational work led by Dr Dennis Slamon revealed that approximately 15%-20% of breast cancers are driven by the overexpressed HER2. This discovery led to the development of trastuzumab, a monoclonal antibody that demonstrated
Source: ascopubs.orgCategories: General Medicine NewsTweet
-
Mashup Score: 83
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer Society. Nevertheless, screenings, early detection and pinpoint therapies have improved patients’ odds, reducing deaths from many cancers, particularly of the breast, lung and prostate. From 2013 to 2022, the overall death […]
Source: rankings.newsweek.comCategories: General Medicine NewsTweet
-
Mashup Score: 83
This year, more than 2 million people in the United States are expected to be diagnosed with some form of cancer, according to the American Cancer Society. Nevertheless, screenings, early detection and pinpoint therapies have improved patients’ odds, reducing deaths from many cancers, particularly of the breast, lung and prostate. From 2013 to 2022, the overall death […]
Source: rankings.newsweek.comCategories: General Medicine NewsTweet
-
Mashup Score: 0How AI is Predicting Prostate Cancer Recurrence - 27 day(s) ago
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes after radical prostatectomy.
Source: my.clevelandclinic.orgCategories: General Medicine NewsTweet
-
Mashup Score: 0How AI is Predicting Prostate Cancer Recurrence - 27 day(s) ago
Christopher Weight, MD, Director of Urologic Oncology at Cleveland Clinic joins the Cancer Advances podcast to discuss using artificial intelligence to predict prostate cancer outcomes after radical prostatectomy.
Source: my.clevelandclinic.orgCategories: General Medicine NewsTweet
-
Mashup Score: 9Chronicling the Extraordinary Career of Stephen R. Grobmyer, MD, FACS, in Breast Cancer Research, Surgery, and Treatment - 29 day(s) ago
In this installment of The ASCO Post’s Living a Full Life series, Stephen R. Grobmyer, MD, FACS, speaks about his clinical and research career in oncology, the challenges and rewards of moving to Abu …
Source: ascopost.comCategories: General Medicine NewsTweet
-
Mashup Score: 7Faculty - 1 month(s) ago
Register for Cleveland Clinic’s 8th Annual Cleveland Breast Cancer Summit: Collaborating for a Cure, Friday August 9, 2024 LIVE at the Intercontinental Hotel & Conference Center. This years summit will focus on the up to date reviews and treatment of early-onset breast cancer
Source: www.clevelandclinicmeded.comCategories: General Medicine NewsTweet
-
Mashup Score: 4Targeted Treatment for NSCLC Effective Across Multiple Populations - 1 month(s) ago
Taletrectinib, an experimental oral next-generation tyrosine kinase inhibitor (TKI), has demonstrated robust clinical activity in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
Source: consultqd.clevelandclinic.orgCategories: General Medicine NewsTweet
https://t.co/9wRXpqzRTz @ClevelandClinic https://t.co/9wRXpqzRTz